Literature DB >> 9291822

Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.

S Chiara1, M T Nobile, C Barzacchi, O Sanguineti, M Vincenti, C Di Somma, P Meszaros, R Rosso.   

Abstract

The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy. 70 advanced colorectal cancer patients (pts) were given weekly 24 h continuous 5-FU (2600 mg/m2) infusion plus L-LV (100 mg/m2 i.v., 50 mg orally). The toxicity, in particular HFS, was analysed, correlated to the main pts characteristics and compared to the other observed side-effects. HFS occurred in 36/70 pts (51%): grade 1 in 16 pts, grade 2 in 16 pts, grade 3 in 3 pts and grade 4 in 1 pt. It occurred after a median number of nine courses. In one case, chemotherapy was interrupted for this toxicity, and in another 5 pts drug reduction and/or treatment delay were undertaken. Changes in the therapeutic programme because of diarrhoea or mucositis were more frequent, even though these toxicities were generally mild in our series of pts. HFS was significantly correlated to previous exposure to chemotherapy (P = 0.00003). HFS was a frequent side-effect of high-dose, short-term continuous 5-FU infusion, but the impact on quality of life of pts and on the correct delivery of the planned chemotherapy was limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291822     DOI: 10.1016/s0959-8049(96)00497-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 3.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

4.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

5.  Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.

Authors:  Yun Zhou; Ling Peng; Yingjie Li; Lixun Chen
Journal:  Biomed Rep       Date:  2013-08-28

6.  Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.

Authors:  Kaori Kadoyama; Akiko Kuwahara; Motohiro Yamamori; J B Brown; Toshiyuki Sakaeda; Yasushi Okuno
Journal:  J Exp Clin Cancer Res       Date:  2011-10-05

7.  Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.

Authors:  Jae Sung Kim; Jun Sang Kim; Moon June Cho; Wan Hee Yoon; Kye Sang Song
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

8.  Preoperative chemoradiation in locally advanced rectal cancer: a comparison of bolus 5-fluorouracil/leucovorin and capecitabine.

Authors:  Adnan Yoney; Levent Isikli
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.